170 related articles for article (PubMed ID: 31136248)
21. [Is prescription of a therapy costing 150,000 CHF reasonable?].
Peters S; von Moos R; Thurlimann B
Rev Med Suisse; 2015 Oct; 11(491):1967-72. PubMed ID: 26672265
[TBL] [Abstract][Full Text] [Related]
22. Availability, Price and Affordability of Anticancer Medicines: Evidence from Two Cross-Sectional Surveys in the Jiangsu Province, China.
Zhu Y; Wang Y; Sun X; Li X
Int J Environ Res Public Health; 2019 Oct; 16(19):. PubMed ID: 31623326
[TBL] [Abstract][Full Text] [Related]
23. Changes in Retail Prices of Prescription Dermatologic Drugs From 2009 to 2015.
Rosenberg ME; Rosenberg SP
JAMA Dermatol; 2016 Feb; 152(2):158-63. PubMed ID: 26606197
[TBL] [Abstract][Full Text] [Related]
24. Analysis of State-Level Drug Pricing Transparency Laws in the United States.
Ryan MS; Sood N
JAMA Netw Open; 2019 Sep; 2(9):e1912104. PubMed ID: 31553467
[TBL] [Abstract][Full Text] [Related]
25. More nonelderly Americans face problems affording prescription drugs.
Felland LE; Reschovsky JD
Track Rep; 2009 Jan; (22):1-4. PubMed ID: 19320083
[TBL] [Abstract][Full Text] [Related]
26. The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs.
Gudiksen KL; King JS
J Leg Med; 2019; 39(2):95-120. PubMed ID: 31503534
[No Abstract] [Full Text] [Related]
27. Plenty of green in gray market. There's more at issue than just inflated prices for drugs in short supply.
May D
Mod Healthc; 2011 Oct; 41(42):25. PubMed ID: 22049782
[No Abstract] [Full Text] [Related]
28. The impact of drug pricing policies on the health of the elderly.
Russell LB; Wolff N
Am J Prev Med; 2002 Apr; 22(3):151-5. PubMed ID: 11897458
[TBL] [Abstract][Full Text] [Related]
29. How The ACA Reframed The Prescription Drug Market And Set The Stage For Current Reform Efforts.
Conti R; Dusetzina SB; Sachs R
Health Aff (Millwood); 2020 Mar; 39(3):445-452. PubMed ID: 32119622
[TBL] [Abstract][Full Text] [Related]
30. What is a fair price for a medicine? Establishing the main elements of a fair price based on the current policy debate.
Roediger A; Schönbächler G; Brand H
Public Health; 2024 Jun; 231():148-153. PubMed ID: 38692089
[TBL] [Abstract][Full Text] [Related]
31. Prescription-price sticker shock: Will federal lawmakers intervene?
Johnson SR
Mod Healthc; 2015 Oct; 45(43):8-9. PubMed ID: 26619614
[No Abstract] [Full Text] [Related]
32. Ensuring access to prescription medications in the post-ACA healthcare access landscape: the essential role of FQHCs in the safety net for the underinsured.
Shi L; Wharton MK; Monnette A
Am J Manag Care; 2018 Mar; 24(5 Suppl):S67-S73. PubMed ID: 29620813
[TBL] [Abstract][Full Text] [Related]
33. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
Danzon PM; Towse A
Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
[TBL] [Abstract][Full Text] [Related]
34. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
[TBL] [Abstract][Full Text] [Related]
35. Prescription drug accessibility and affordability in the United States and abroad.
Morgan S; Kennedy J
Issue Brief (Commonw Fund); 2010 Jun; 89():1-12. PubMed ID: 20614652
[TBL] [Abstract][Full Text] [Related]
36. How to Reduce Prescription Drug Prices: First, Do No Harm.
Atlas S
Mo Med; 2020; 117(1):14-15. PubMed ID: 32158034
[No Abstract] [Full Text] [Related]
37. [Drug prices: how they are established and existing price control systems].
Rovira Forns J
Salud Colect; 2015 Mar; 11(1):35-48. PubMed ID: 25853829
[TBL] [Abstract][Full Text] [Related]
38. Determinants of Market Exclusivity for Prescription Drugs in the United States.
Kesselheim AS; Sinha MS; Avorn J
JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
[TBL] [Abstract][Full Text] [Related]
39. Trends in Prescription Drug Launch Prices, 2008-2021.
Rome BN; Egilman AC; Kesselheim AS
JAMA; 2022 Jun; 327(21):2145-2147. PubMed ID: 35670795
[TBL] [Abstract][Full Text] [Related]
40. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
